Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.
Underdog Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.
Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease. Its co-founders are Matthew O’Connor, Ph.D., and Michael Kope, formerly the Vice President of Research and the founding Chief Executive Officer, respectively, of SRF.
Visit website: https://underdogpharma.com/
See also: SENS Research Foundation
People at Underdog Pharmaceuticals
Co-Chief Executive Officer and Co-founder of Underdog Pharmaceuticals.
Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals
Underdog Pharmaceuticals News
Two drug molecules delivered via nanoparticles to combat atherosclerosis
Life Extension Advocacy Foundation (LEAF) - 26-Jun-2020
Success in mice model gives hope for fighting cholesterol-associated inflammatory diseasesRead more...
Fight Aging! reports back from SENS Research Foundation Pitch Day - Part 1
Fight Aging! - 20-Jan-2020
A stunning array of ideas - any of which on their own would be truly revolutionaryRead more...